Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IsraelIPO:
01 September 2005Website:
http://www.xtlbio.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 107 min agoDividend
Analysts recommendations
Institutional Ownership
What type of business is XTL Biopharmaceuticals?
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
What sector is XTL Biopharmaceuticals in?
XTL Biopharmaceuticals is in the Healthcare sector
What industry is XTL Biopharmaceuticals in?
XTL Biopharmaceuticals is in the Biotechnology industry
What country is XTL Biopharmaceuticals from?
XTL Biopharmaceuticals is headquartered in Israel
When did XTL Biopharmaceuticals go public?
XTL Biopharmaceuticals initial public offering (IPO) was on 01 September 2005
What is XTL Biopharmaceuticals website?
https://www.xtlbio.com
Is XTL Biopharmaceuticals in the S&P 500?
No, XTL Biopharmaceuticals is not included in the S&P 500 index
Is XTL Biopharmaceuticals in the NASDAQ 100?
No, XTL Biopharmaceuticals is not included in the NASDAQ 100 index
Is XTL Biopharmaceuticals in the Dow Jones?
No, XTL Biopharmaceuticals is not included in the Dow Jones index
When does XTL Biopharmaceuticals report earnings?
The next expected earnings date for XTL Biopharmaceuticals is 09 August 2024